<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988686</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-065</org_study_id>
    <nct_id>NCT03988686</nct_id>
  </id_info>
  <brief_title>Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone</brief_title>
  <official_title>Zhongshan Hospital, Fudan University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine whether radical prostatectomy can impact survival and
      quality-of-life in men with oligo-metastatic prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with oligo-metastatic prostate cancer will be randomized to radical
      prostatectomy plus standard care and standard care only. Standard care refers to androgen
      deprivation therapy (ADT) +/- other systemic therapies. Time to disease progression and
      post-treatment quality of life will be assessed and compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the time to castrate resistance</measure>
    <time_frame>36 months after randomization</time_frame>
    <description>The time to treatment failure defined as castrate resistance will be recorded via routine patient follow-up interviews.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in patients post-randomization</measure>
    <time_frame>three month post randomization</time_frame>
    <description>EuroQOL 5 dimensions 5 levels (EQ-5D-5L) questionnaire will be used to assess quality of life in patients after randomization with different treatments. This is designed to measure health-related quality of life. It consists of a questionnaire and a visual analogue scale. The subjects in 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression are asked to grade their own current level of function in each dimension into one of five levels of disability (i.e. I have no problems waling about, slight problems, moderate problems, severe problems, or unable to walk). This tool also has an overall health scale where the rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical prostatectomy plus standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care, currently ADT +/- other systemic therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy plus standard care</intervention_name>
    <description>To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care for metastatic prostate cancer</intervention_name>
    <description>androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer</description>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants is willing and able to give informed consent for participation in the
             study

          -  Male aged 19-75 years.

          -  Diagnosed with oligo-metastatic prostate cancer (1-3 skeletal lesions on bone specific
             imaging, no visceral metastases).

          -  Locally resectable tumor (clinical/radiological stage T1-T3).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Suitable for radical prostatectomy within 12 months of starting standard care.

        Exclusion Criteria:

          -  Contraindications to radical prostatectomy.

          -  Visceral metastases.

          -  Prior radiotherapy to the abdomen/pelvis or to skeletal metastases.

          -  Any systemic therapy of prostate cancer (including standard care) for 12 or more
             months prior to enrollment.

          -  Current involvement in other interventional research.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-Ming Guo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian-Ming Guo, MD, PhD</last_name>
    <phone>+86 13681971306</phone>
    <email>guo.jianming@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Xu, MD, PhD</last_name>
    <phone>+86 18616139981</phone>
    <email>xu.lei1@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Ming Guo, MD, PhD</last_name>
      <phone>+86 13681971306</phone>
      <email>guo.jianming@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lei Xu, MD, PhD</last_name>
      <phone>+86 18616139981</phone>
      <email>xu.lei1@zs-hospital.sh.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 8, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jianming Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oligometastasis</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>radical prostatectomy</keyword>
  <keyword>progression-free survival</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

